These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 22786770)

  • 41. Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site.
    Jokiranta TS; Cheng ZZ; Seeberger H; Jòzsi M; Heinen S; Noris M; Remuzzi G; Ormsby R; Gordon DL; Meri S; Hellwage J; Zipfel PF
    Am J Pathol; 2005 Oct; 167(4):1173-81. PubMed ID: 16192651
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome.
    Józsi M; Strobel S; Dahse HM; Liu WS; Hoyer PF; Oppermann M; Skerka C; Zipfel PF
    Blood; 2007 Sep; 110(5):1516-8. PubMed ID: 17495132
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies.
    Boyer O; Balzamo E; Charbit M; Biebuyck-Gougé N; Salomon R; Dragon-Durey MA; Frémeaux-Bacchi V; Niaudet P
    Am J Kidney Dis; 2010 May; 55(5):923-7. PubMed ID: 20202729
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles.
    Skerka C; Licht C; Mengel M; Uzonyi B; Strobel S; Zipfel PF; Józsi M
    Mol Immunol; 2009 Sep; 46(14):2801-7. PubMed ID: 19640589
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory statesthe examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration.
    Richards A; Kavanagh D; Atkinson JP
    Adv Immunol; 2007; 96():141-77. PubMed ID: 17981206
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overactivation of Complement Alternative Pathway in Postpartum Atypical Hemolytic Uremic Syndrome Patients with Renal Involvement.
    Song D; Yu XJ; Wang FM; Xu BN; He YD; Chen Q; Wang SX; Yu F; Song WC; Zhao MH
    Am J Reprod Immunol; 2015 Oct; 74(4):345-56. PubMed ID: 26011580
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Heterogeneity but individual constancy of epitopes, isotypes and avidity of factor H autoantibodies in atypical hemolytic uremic syndrome.
    Nozal P; Bernabéu-Herrero ME; Uzonyi B; Szilágyi Á; Hyvärinen S; Prohászka Z; Jokiranta TS; Sánchez-Corral P; López-Trascasa M; Józsi M
    Mol Immunol; 2016 Feb; 70():47-55. PubMed ID: 26703217
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome.
    Richards A; Kathryn Liszewski M; Kavanagh D; Fang CJ; Moulton E; Fremeaux-Bacchi V; Remuzzi G; Noris M; Goodship TH; Atkinson JP
    Mol Immunol; 2007 Jan; 44(1-3):111-22. PubMed ID: 16882452
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD).
    Fritsche LG; Lauer N; Hartmann A; Stippa S; Keilhauer CN; Oppermann M; Pandey MK; Köhl J; Zipfel PF; Weber BH; Skerka C
    Hum Mol Genet; 2010 Dec; 19(23):4694-704. PubMed ID: 20843825
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models.
    Saunders RE; Abarrategui-Garrido C; Frémeaux-Bacchi V; Goicoechea de Jorge E; Goodship TH; López Trascasa M; Noris M; Ponce Castro IM; Remuzzi G; Rodríguez de Córdoba S; Sánchez-Corral P; Skerka C; Zipfel PF; Perkins SJ
    Hum Mutat; 2007 Mar; 28(3):222-34. PubMed ID: 17089378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. C-reactive protein and pentraxin-3 binding of factor H-like protein 1 differs from complement factor H: implications for retinal inflammation.
    Swinkels M; Zhang JH; Tilakaratna V; Black G; Perveen R; McHarg S; Inforzato A; Day AJ; Clark SJ
    Sci Rep; 2018 Jan; 8(1):1643. PubMed ID: 29374201
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association among Complement Factor H Autoantibodies, Deletions of CFHR, and the Risk of Atypical Hemolytic Uremic Syndrome.
    Jiang H; Fan MN; Yang M; Lu C; Zhang M; Liu XH; Ma L
    Int J Environ Res Public Health; 2016 Dec; 13(12):. PubMed ID: 27929404
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS).
    Westra D; Volokhina E; van der Heijden E; Vos A; Huigen M; Jansen J; van Kaauwen E; van der Velden T; van de Kar N; van den Heuvel L
    Nephrol Dial Transplant; 2010 Jul; 25(7):2195-202. PubMed ID: 20106822
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome.
    Francis NJ; McNicholas B; Awan A; Waldron M; Reddan D; Sadlier D; Kavanagh D; Strain L; Marchbank KJ; Harris CL; Goodship TH
    Blood; 2012 Jan; 119(2):591-601. PubMed ID: 22058112
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Standardisation of the factor H autoantibody assay.
    Watson R; Lindner S; Bordereau P; Hunze EM; Tak F; Ngo S; Zipfel PF; Skerka C; Dragon-Durey MA; Marchbank KJ
    Immunobiology; 2014 Jan; 219(1):9-16. PubMed ID: 23891327
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation.
    Valoti E; Alberti M; Tortajada A; Garcia-Fernandez J; Gastoldi S; Besso L; Bresin E; Remuzzi G; Rodriguez de Cordoba S; Noris M
    J Am Soc Nephrol; 2015 Jan; 26(1):209-19. PubMed ID: 24904082
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Functional characterization of two novel non-synonymous alterations in CD46 and a Q950H change in factor H found in atypical hemolytic uremic syndrome patients.
    Mohlin FC; Nilsson SC; Levart TK; Golubovic E; Rusai K; Müller-Sacherer T; Arbeiter K; Pállinger É; Szarvas N; Csuka D; Szilágyi Á; Villoutreix BO; Prohászka Z; Blom AM
    Mol Immunol; 2015 Jun; 65(2):367-76. PubMed ID: 25733390
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation.
    Nilsson SC; Karpman D; Vaziri-Sani F; Kristoffersson AC; Salomon R; Provot F; Fremeaux-Bacchi V; Trouw LA; Blom AM
    Mol Immunol; 2007 Mar; 44(8):1835-44. PubMed ID: 17084897
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The long pentraxin PTX3 as a link among innate immunity, inflammation, and female fertility.
    Bottazzi B; Bastone A; Doni A; Garlanda C; Valentino S; Deban L; Maina V; Cotena A; Moalli F; Vago L; Salustri A; Romani L; Mantovani A
    J Leukoc Biol; 2006 May; 79(5):909-12. PubMed ID: 16478917
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome.
    Goicoechea de Jorge E; Tortajada A; García SP; Gastoldi S; Merinero HM; García-Fernández J; Arjona E; Cao M; Remuzzi G; Noris M; Rodríguez de Córdoba S
    J Am Soc Nephrol; 2018 Jan; 29(1):240-249. PubMed ID: 28993505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.